Compugen to receive $5M milestone payment from AstraZeneca

Compugen (CGEN) is entitled to receive a $5M milestone payment from AstraZeneca (AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca’s PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen’s clinical-stage anti-TIGIT antibody, COM902. The trial is evaluating the efficacy and safety of rilvegostomig as monotherapy and in combination with datopotamab deruxtecan, AstraZeneca and Daiichi Sankyo’s (DSNKY) TROP2-directed antibody drug conjugate versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo. The ARTEMIDE-Biliary01 Phase 3 trial is evaluating the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator’s choice of chemotherapy in patients with biliary tract cancer after surgical resection with curative intent.